This study will evaluate the effects of a protein called secretory leukocyte protease
inhibitor (SLPI), on skin wound healing. Produced naturally by the body, SLPI modifies levels
of elastase, a substance that breaks down the skin. Older people are at greater risk of
impaired wound healing, with increased elastase activity and inflammation. In addition, men
heal more slowly than women. Delayed healing is associated with infection and pain and can
lead to the development of chronic non-healing skin wounds.
Healthy men and women between 60 and 80 years old who wish to participate in this study will
have a brief history and physical evaluation to determine their eligibility. Those enrolled
will be randomly assigned to receive a gel form of SLPI applied topically (on the skin
surface) to a skin wound or a placebo (a look-alike gel with no active ingredient).
Participants will undergo the following procedures:
First visit - The skin will be numbed with a local anesthetic and two small (4 mm) wounds
(about the size of a pencil eraser) made in each upper arm. The drug or placebo will be
applied to the wound and gauze placed over it. Two blood samples (20 ml and 7 ml) will be
drawn an hour apart to determine blood levels of SLPI.
Second visit - The day after the first visit, the wound dressing will be removed and the
participant will be evaluated for pain at the wound site, allergic reactions or infection. A
blood sample (7 ml) will be taken.
Third visit - The wounds will be examined and photographed to evaluate healing. In addition,
the strength of the wound may be assessed by means of a vacuum system placed on the skin.
(This may cause a tingling sensation over the wound.) A piece of all four wounds will be
removed after the skin has been numbed and a dressing applied.
Fourth visit - The wounds will be examined for healing and the dressing removed.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Dental and Craniofacial Research (NIDCR)